Clinical Trial Update: mFOLFOX6+Bevacizumab+PD-1 Monoclonal Antibody in Local Advanced MSS CRC [Phase 2]

View source ↗

Summary

Phase 2 study of mFOLFOX6 plus Bevacizumab and a PD-1 monoclonal antibody in locally advanced microsatellite-stable colorectal cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• PD-1 monoclonal antibody
• mFOLFOX6 regimen

Snippet

Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University | Conditions: Colorectal Cancer, Immunotherapy | Phase 2 | Status: COMPLETED